4/3
08:14 pm
dnli
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up [Yahoo! Finance]
High
Report
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up [Yahoo! Finance]
4/2
08:00 am
dnli
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
Medium
Report
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
3/10
01:15 pm
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at Bank of America Co. from $30.00 to $28.00. They now have a "buy" rating on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at Bank of America Co. from $30.00 to $28.00. They now have a "buy" rating on the stock.
3/7
10:01 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $33.00 price target on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $33.00 price target on the stock.
3/5
12:24 pm
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $35.00 price target on the stock, down previously from $38.00.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $35.00 price target on the stock, down previously from $38.00.
3/3
01:13 pm
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $50.00 to $42.00. They now have an "outperform" rating on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $50.00 to $42.00. They now have an "outperform" rating on the stock.
2/28
03:13 pm
dnli
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus [Yahoo! Finance]
Low
Report
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus [Yahoo! Finance]
2/28
12:30 pm
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "outperform" rating re-affirmed by analysts at William Blair.
Medium
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "outperform" rating re-affirmed by analysts at William Blair.
2/28
08:13 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target raised by analysts at HC Wainwright from $80.00 to $87.00. They now have a "buy" rating on the stock.
High
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target raised by analysts at HC Wainwright from $80.00 to $87.00. They now have a "buy" rating on the stock.
2/27
04:01 pm
dnli
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
High
Report
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
2/11
07:26 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating and a $31.00 price target on the stock.
Medium
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating and a $31.00 price target on the stock.
2/6
01:43 pm
dnli
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa [Yahoo! Finance]
Low
Report
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa [Yahoo! Finance]
2/6
11:42 am
dnli
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
Medium
Report
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
1/30
08:36 am
dnli
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™ [Yahoo! Finance]
Low
Report
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™ [Yahoo! Finance]
1/30
08:00 am
dnli
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
Low
Report
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
1/28
10:44 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $45.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $45.00 to $40.00. They now have a "buy" rating on the stock.
1/15
08:13 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "outperform" rating re-affirmed by analysts at William Blair.
High
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "outperform" rating re-affirmed by analysts at William Blair.
1/14
10:16 am
dnli
Denali Therapeutics' ALS therapy fails to meet primary endpoint in Phase II/III trial [Yahoo! Finance]
Low
Report
Denali Therapeutics' ALS therapy fails to meet primary endpoint in Phase II/III trial [Yahoo! Finance]
1/14
10:16 am
dnli
More on DNLI's Tividenofusp Alfa [Yahoo! Finance]
Low
Report
More on DNLI's Tividenofusp Alfa [Yahoo! Finance]
1/14
10:16 am
dnli
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases [Yahoo! Finance]
Neutral
Report
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases [Yahoo! Finance]
1/13
08:00 am
dnli
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
Low
Report
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
1/8
08:53 am
dnli
Denali Therapeutics gets FDA breakthrough therapy designation for its treatment of hunter syndrome [Seeking Alpha]
Low
Report
Denali Therapeutics gets FDA breakthrough therapy designation for its treatment of hunter syndrome [Seeking Alpha]
1/8
08:00 am
dnli
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
Low
Report
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
1/8
07:20 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) was upgraded by analysts at Baird R W to a "strong-buy" rating.
High
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) was upgraded by analysts at Baird R W to a "strong-buy" rating.
1/7
02:30 pm
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at JPMorgan Chase & Co. from $28.00 to $24.00. They now have an "overweight" rating on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at JPMorgan Chase & Co. from $28.00 to $24.00. They now have an "overweight" rating on the stock.